Galmed announces grant of new patent for the combination of aramchol with resmetirom (mgl-3196, rezdiffra) for the treatment of nash and liver fibrosis

Tel aviv, israel , march 15, 2024 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the grant of a european patent related to the use of a combination of aramchol and resmetirom (mgl-3196, rezdiffra) for the treatment of nash/mash and liver fibrosis.
GLMD Ratings Summary
GLMD Quant Ranking